Kappa Opioid Receptor Peptide Agonists for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kappa opioid receptor peptide agonists for pain and pruritus often suffer from side effects such as diuresis, sedation, dysphoria, and lack of efficacy, limiting their clinical effectiveness as analgesics and anti-pruritic agents.
Innovation Solution
Development of novel kappa opioid receptor peptide agonists with specific structural modifications, such as those described in Formula (I), which combine specific amino acids to enhance analgesic and anti-pruritus effects while minimizing conventional morphinan analgesic side effects, along with methods for their synthesis and pharmaceutical compositions for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional KOR ligands are used as analgesics, then pain relief is achieved, but side effects such as diuresis, sedation, and dysphoria occur
Solution Approach 1:
The patent modifies the chemical structure of KOR ligands by changing parameters such as introducing specific amino acid sequences (D-Phe-D-Phe-D-Leu-D-Lys), modifying the C-terminal residue, and adjusting molecular weight and hydrophobicity. These parameter changes result in new compounds that maintain analgesic efficacy while reducing side effects like diuresis and sedation.
Solution Approach 2:
The patent creates composite peptide structures by combining specific amino acid residues in a tetrapeptide sequence. The composite structure of D-Phe-D-Phe-D-Leu-D-Lys with various C-terminal modifications produces a synergistic effect that enhances analgesic activity while minimizing conventional side effects through the combined properties of the peptide sequence and terminal group.
2Object-generated harmful factors
If peptide-based KOR agonists are developed to avoid morphinan side effects, then side effect profile improves, but therapeutic efficacy and selectivity must be optimized
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular locations in the peptide sequence. The C-terminal residue is specifically modified with groups like carboxylic acid, ester, or amide that locally enhance binding affinity to KOR, while the N-terminal D-Phe-D-Phe sequence provides local selectivity and reduces side effects. This localized optimization achieves both improved side effect profile and maintained therapeutic efficacy.
3Reliability
If structural modifications are made to enhance analgesic effects, then therapeutic efficacy improves, but synthesis complexity increases
Solution Approach 1:
The patent segments the peptide synthesis into modular steps: first synthesizing the core D-Phe-D-Phe-D-Leu-D-Lys tetrapeptide sequence, then separately introducing different C-terminal groups. This segmentation allows the common peptide backbone to be synthesized once and reused, while only the terminal group needs to be modified for each specific compound, significantly reducing overall synthesis complexity compared to de novo synthesis of each variant.
Data Source
AI summary
The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.